| Sep 17 |
BioMarin Pharmaceutical: A Volatile But Growing Trajectory
|
| Sep 17 |
Ascendis trial data piles pressure on BioMarin
|
| Sep 16 |
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
|
| Sep 16 |
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
|
| Sep 16 |
BioMarin off 17% as Ascendis data seen as threat to Voxzogo
|
| Sep 13 |
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
|
| Sep 8 |
BioMarin Pharmaceutical Inc. (BMRN): Is This Biotech Stock A Good Buy?
|
| Sep 5 |
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
|
| Sep 4 |
BioMarin plans $500M cost transformation to improve margins
|
| Sep 4 |
BioMarin, having retrenched, outlines plans for growth
|
